Acumen Pharmaceuticals (ABOS) Share-based Compensation (2020 - 2026)

Acumen Pharmaceuticals' Share-based Compensation history runs 7 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 3.15% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $9.8 million (up 1.55% YoY), while the FY2025 annual figure was $9.9 million, up 2.25% from the prior year.
• Share-based Compensation came in at $2.4 million for Q1 2026 at Acumen Pharmaceuticals, down from $2.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q2 2025 to a low of $618000.0 in Q1 2022.
• A 5-year average of $1.8 million and a median of $2.3 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 462.99% in 2022 and slipped 3.15% in 2026, its largest moves.
• Acumen Pharmaceuticals' Share-based Compensation stood at $888000.0 in 2022, then surged by 84.01% to $1.6 million in 2023, then jumped by 43.39% to $2.3 million in 2024, then climbed by 3.24% to $2.4 million in 2025, then dropped by 0.95% to $2.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.4 million, $2.4 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison